Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2012

View Archived Issues

Team at Merrimack Pharmaceuticals designs new bispecific antibodies

AstraZeneca profiles novel dual chemokine CCR3/histamine H1 receptor antagonists

Gilead's GS-967 suppresses experimental arrhythmias

New TRPV4 channel ligands divulged by Shionogi

Promising results presented for a novel malaria vaccine

Novel antipsychotics created at Roche

King Saud University and Terramark design new anti-inflammatory agents

Arena Pharmaceuticals divulges novel GRP119 receptor agonists

Ligand Pharmaceuticals presents a novel HepDirect prodrug with excellent oral bioavailability

Enhanced genetically encoded calcium indicators described / News in Context: Optogenetics

ImmunoGen patents novel cancer therapeutics

New antivirals designed by University of Pennsylvania

University of Missouri discloses novel TNF-alpha production inhibitors

EMA recommends granting orphan status to Aspireo's somatoprim

GS-432780-5 and GS-443023-6 show promise in mouse models of chronic liver injury

Alfama designs novel therapy against liver pathology

Discovery of AZ-12436092 reported by AstraZeneca researchers

Pharming receives milestone payment from Santarus

CLSPN gene mutations identified in glioma patients

Phase IIb JX-594 trial begins in Hong Kong

Murdoch Childrens opens Australian site in global study of BioMarin's achondroplasia treatment

AstraZeneca and Pfizer partnership establishes life sciences research center

Recruitment complete in phase I study of ATX-MS-1467

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...